CNTNAP2 and schizophrenia: For instance, variable dosage of CNTNAP2 has also been documented in epilepsy and schizophrenia (11), while deletion of 15q13.3 has been implicated in autism (12), generalized learning disability (13), epilepsy (14), and schizophrenia (15).